Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315020 | 0.89 | — | — | |
| SCHEMBL699953 | 0.74 | CPN1 (0.30) | — | |
| SCHEMBL8245494 | 0.72 | CYP2D6 (0.47) | BRD4THRBATML3MBTL1CHRNB2 | |
| SCHEMBL13498638 | 0.70 | BRD4 (0.47) | BRD4THRBATML3MBTL1CYP2D6 | |
| SCHEMBL8286682 | 0.70 | BRD4 (0.49) | BRD4THRBATML3MBTL1CHRNB2 | |
| SCHEMBL13597243 | 0.68 | POLB (0.48) | BRD4THRBATML3MBTL1GAA | |
| SCHEMBL13832733 | 0.68 | BRD4 (0.42) | BRD4THRBATML3MBTL1CHRNB2 | |
| SCHEMBL13832731 | 0.68 | BRD4 (0.42) | BRD4THRBATML3MBTL1CHRNB2 | |
| SCHEMBL10191757 | 0.67 | BRD4 (0.43) | BRD4CTSKTHRBATML3MBTL1 | |
| SCHEMBL30803864 | 0.67 | BRD4 (0.43) | BRD4CTSKTHRBATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113793-A1 | Process for the Preparation of Highly Pure Donepezil | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100105916-A1 | Processes for Preparing Donepezil | Sterling Biotech Limited (IN) | 2010-04-29 | — | — | US | disclosed |
| WO-2007108011-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE DONEPEZIL | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-09-27 | — | — | WO | disclosed |
| EP-1531151-B1 | A process for the preparation of 1-benzyl-4-¬(5,6-dimethoxy-1-indanon)-2-yl| methyl piperidine hydrochloride (donepezil hcl) | USV LTD (IN) | 2007-03-07 | — | — | EP | disclosed |
| US-6953856-B2 | Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) | USV, LIMITED (IN) | 2005-10-11 | — | — | US | disclosed |
| EP-1531151-A1 | A process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine hydrochloride (donepezil hcl) | USV Limited (IN) | 2005-05-18 | — | — | EP | disclosed |
| US-20040158070-A1 | Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) | USV LIMITED, BSD MARG. (IN) | 2004-08-12 | — | — | US | disclosed |
| US-6649765-B1 | Hydrogenating 5,6-Dimethoxy-2-(pyridin-4-yl)methylene indan-1-one in the presence of catalysts, then alkylating with benzyl bromide, to form drugs used for prophylaxis of nervous system disorders; by product inhibition | USV LIMITED, BSD MARG. (IN) | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113793-A1 | Process for the Preparation of Highly Pure Donepezil | PSEN1, ACHE, PSEN2 | BRD4 1890/4885CTSK 2012/4885THRB 4506/4885 |
| US-20040158070-A1 | Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) | HCN1, HNMT, H1-5 | BRD4 472/4885CTSK 2617/4885THRB 4268/4885 |
| US-20100105916-A1 | Processes for Preparing Donepezil | HNMT, PNMT, PSEN1 | BRD4 882/4885CTSK 2285/4885THRB 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.